학술논문
Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.
Document Type
Article
Author
Source
Subject
*RESEARCH
*GENETIC mutation
*CHOLANGIOCARCINOMA
*CANCER chemotherapy
*BRCA genes
*ACQUISITION of data
*RETROSPECTIVE studies
*PLATINUM
*TREATMENT effectiveness
*CANCER patients
*COMPARATIVE studies
*MEDICAL records
*DESCRIPTIVE statistics
*RESEARCH funding
*DRUG allergy
*HEPATOCELLULAR carcinoma
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0735-7907
Abstract
Preclinical data suggest that IDH1/2 mutations result in defective homologous recombination repair (HRR). We hypothesized that patients with IDH1/2mt intrahepatic cholangiocarcinoma (IHCC) would benefit more from 1 L platinum chemotherapy than patients with wildtype (WT) tumors. We performed a multicenter retrospective study of 81 patients with unresectable IHCC treated with 1 L platinum with a primary endpoint of clinical benefit rate (CBR). Patients with IDH1/2mt tumors had a similar CBR and objective response rate compared to those with IDH WT disease (59 versus 54%; p = 0.803), suggesting that a relationship between platinum sensitivity and HRR gene defects may be specific to tumor context. [ABSTRACT FROM AUTHOR]